JP6831802B2 - 放射性核種標識化合物及びこれを含有するイメージング剤 - Google Patents

放射性核種標識化合物及びこれを含有するイメージング剤 Download PDF

Info

Publication number
JP6831802B2
JP6831802B2 JP2018003564A JP2018003564A JP6831802B2 JP 6831802 B2 JP6831802 B2 JP 6831802B2 JP 2018003564 A JP2018003564 A JP 2018003564A JP 2018003564 A JP2018003564 A JP 2018003564A JP 6831802 B2 JP6831802 B2 JP 6831802B2
Authority
JP
Japan
Prior art keywords
radionuclide
tau
salt
labeled compound
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018003564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019123675A (ja
JP2019123675A5 (enExample
Inventor
斌 季
斌 季
真人 樋口
真人 樋口
哲也 須原
哲也 須原
忠正 陳
忠正 陳
央介 藤本
央介 藤本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Chartwell Medical Instrument Co Ltd
Original Assignee
Shanghai Chartwell Medical Instrument Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Chartwell Medical Instrument Co Ltd filed Critical Shanghai Chartwell Medical Instrument Co Ltd
Priority to JP2018003564A priority Critical patent/JP6831802B2/ja
Priority to TW108101192A priority patent/TWI818946B/zh
Priority to CN201980007415.2A priority patent/CN111556868B/zh
Priority to KR1020207023105A priority patent/KR102428569B1/ko
Priority to PCT/IB2019/000060 priority patent/WO2019138296A2/ja
Publication of JP2019123675A publication Critical patent/JP2019123675A/ja
Publication of JP2019123675A5 publication Critical patent/JP2019123675A5/ja
Application granted granted Critical
Publication of JP6831802B2 publication Critical patent/JP6831802B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018003564A 2018-01-12 2018-01-12 放射性核種標識化合物及びこれを含有するイメージング剤 Active JP6831802B2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2018003564A JP6831802B2 (ja) 2018-01-12 2018-01-12 放射性核種標識化合物及びこれを含有するイメージング剤
TW108101192A TWI818946B (zh) 2018-01-12 2019-01-11 放射性核種標識化合物及含有其之成像劑
CN201980007415.2A CN111556868B (zh) 2018-01-12 2019-01-11 放射性核素标记化合物和含有该化合物的显影剂
KR1020207023105A KR102428569B1 (ko) 2018-01-12 2019-01-11 방사성 핵종 표지 화합물 및 이것을 함유하는 이미징제
PCT/IB2019/000060 WO2019138296A2 (ja) 2018-01-12 2019-01-11 放射性核種標識化合物及びこれを含有するイメージング剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018003564A JP6831802B2 (ja) 2018-01-12 2018-01-12 放射性核種標識化合物及びこれを含有するイメージング剤

Publications (3)

Publication Number Publication Date
JP2019123675A JP2019123675A (ja) 2019-07-25
JP2019123675A5 JP2019123675A5 (enExample) 2020-09-17
JP6831802B2 true JP6831802B2 (ja) 2021-02-17

Family

ID=67218458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018003564A Active JP6831802B2 (ja) 2018-01-12 2018-01-12 放射性核種標識化合物及びこれを含有するイメージング剤

Country Status (5)

Country Link
JP (1) JP6831802B2 (enExample)
KR (1) KR102428569B1 (enExample)
CN (1) CN111556868B (enExample)
TW (1) TWI818946B (enExample)
WO (1) WO2019138296A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115989029B (zh) * 2020-08-25 2025-07-22 国立研究开发法人量子科学技术研究开发机构 化合物、α突触核蛋白凝集体结合剂及其利用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1381604B1 (en) * 2001-04-23 2006-12-27 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
WO2005016888A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
US8022075B2 (en) * 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
CN101466711A (zh) * 2006-05-19 2009-06-24 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的新化合物
WO2008078424A1 (ja) * 2006-12-25 2008-07-03 Tohoku University ベンゾキサゾール誘導体
JP4738443B2 (ja) * 2007-05-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患のイメージング薬及び治療薬
JP2011524864A (ja) * 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール
AU2012259929B2 (en) * 2011-05-20 2016-08-04 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
JP5167436B2 (ja) * 2011-06-24 2013-03-21 日本メジフィジックス株式会社 新規アミロイド親和性化合物
AU2012397435B2 (en) * 2012-12-21 2017-03-30 National Institutes For Quantum And Radiological Science And Technology Novel compound for imaging TAU protein accumulated in the brain
JP6130055B2 (ja) * 2013-05-23 2017-05-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 造影剤としての２−フェニルイミダゾ［１．２−ａ］ピリミジン

Also Published As

Publication number Publication date
TW201929909A (zh) 2019-08-01
CN111556868A (zh) 2020-08-18
KR102428569B1 (ko) 2022-08-03
TWI818946B (zh) 2023-10-21
JP2019123675A (ja) 2019-07-25
WO2019138296A2 (ja) 2019-07-18
WO2019138296A3 (ja) 2019-10-03
CN111556868B (zh) 2023-03-28
KR20200109335A (ko) 2020-09-22

Similar Documents

Publication Publication Date Title
Ono et al. Benzofuran derivatives as Aβ-aggregate-specific imaging agents for Alzheimer’s disease
Zhuang et al. IBOX (2-(4′-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain
Ono et al. Novel chalcones as probes for in vivo imaging of β-amyloid plaques in Alzheimer’s brains
Ono et al. Development of novel β-amyloid probes based on 3, 5-diphenyl-1, 2, 4-oxadiazole
JP5272110B2 (ja) 新規アミロイド親和性化合物
Ono et al. Development of novel 123I-labeled pyridyl benzofuran derivatives for SPECT imaging of β-amyloid plaques in Alzheimer’s disease
JP4234425B2 (ja) アルツハイマー病を診断するための放射性医薬
Matsumura et al. Synthesis and biological evaluation of novel styryl benzimidazole derivatives as probes for imaging of neurofibrillary tangles in Alzheimer’s disease
JP2010524965A (ja) ジフェニル−ヘテロアリール誘導体並びにアミロイド斑への結合及び画像化のためのその使用
JPWO2009054496A1 (ja) 新規アミロイド親和性化合物
Fuchigami et al. Synthesis and evaluation of ethyleneoxylated and allyloxylated chalcone derivatives for imaging of amyloid β plaques by SPECT
Wang et al. 99mTc-labeled-2-arylbenzoxazole derivatives as potential Aβ imaging probes for single-photon emission computed tomography
Nan et al. 6-Methoxy-indanone derivatives as potential probes for β-amyloid plaques in Alzheimer's disease
Ono et al. Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer's disease
JP6831802B2 (ja) 放射性核種標識化合物及びこれを含有するイメージング剤
JP6260967B2 (ja) 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
JP5954737B2 (ja) 放射性フッ素標識キノキサリン化合物
Watanabe et al. Synthesis and biological evaluation of radioiodinated 2, 5-diphenyl-1, 3, 4-oxadiazoles for detecting β-amyloid plaques in the brain
Neumaier et al. Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease
JP2013237655A (ja) コンフォメーション病診断用分子プローブ
CN108290883B (zh) 用于tau成像的氮杂环丁烷衍生物
JP2006514928A (ja) アミロイドタンパク質線維の形成に関連する疾患を診断および監視するために利用できる化合物
HK40030316B (en) Radionuclide-labeled compound and imaging agent containing same
HK40030316A (en) Radionuclide-labeled compound and imaging agent containing same
JPWO2014132919A1 (ja) 診断用組成物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200805

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200805

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210129

R150 Certificate of patent or registration of utility model

Ref document number: 6831802

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250